MX-4509

MIGENIX Reports First Quarter Fiscal Year 2007 Financial Results: Financial News - Yahoo! Finance: "The decrease in clinical program development costs from Q1/06 to Q1/07 was primarily due to a decrease in MX-4509 program costs resulting from the Q1/06 decision to pursue potential orphan indications, and not proceeding with a planned phase I/II trial in Alzheimer's patients. "